Last quarter (Q ), China SXT Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q, China SXT Pharmaceuticals's net income was $―. See China SXT Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	-	$ 1.97M	$ 2.60M	$ 4.78M	$ 5.16M	$ 7.01M
Cost of Revenue	-	$ 1.55M	$ 1.35M	$ 1.94M	$ 2.46M	$ 2.40M
Gross Profit	-	$ 426.27K	$ 1.25M	$ 2.84M	$ 2.70M	$ 4.61M
Operating Expense	-	$ 6.03M	$ 6.44M	$ 5.04M	$ 4.04M	$ 2.84M
Operating Income	-	$ -4.06M	$ -5.19M	$ -2.20M	$ -1.34M	$ 1.77M
Net Non Operating Interest Income Expense	-	$ -476.78K	$ -36.70K	$ -1.62M	$ -3.35M	$ -5.17K
Other Income Expense	-	$ -149.51K	$ 181.58K	$ 871.65K	$ -5.70M	$ 27.14K
Pretax Income	-	$ -10.32M	$ -10.82M	$ -2.94M	$ -10.39M	$ 1.79M
Tax Provision	-	-	$ 328.15K	$ -192.68K	$ -101.72K	$ 252.23K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	$ -5.93M	$ -5.74M	$ -2.75M	$ -10.29M	$ 1.54M
Basic EPS	-	$ -0.89	$ -110.40	$ -3.82	$ -1.66	$ 0.30
Diluted EPS	-	$ -0.89	$ -110.40	$ -3.82	$ -1.66	$ 0.30
Basic Average Shares	-	$ 6.67M	$ 51.99K	$ 719.55K	$ 6.18M	$ 5.14M
Diluted Average Shares	-	$ 6.67M	$ 51.96K	$ 719.55K	$ 6.18M	$ 5.14M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	$ 7.58M	$ 7.79M	$ 6.97M	$ 6.50M	$ 5.24M
Net Income From Continuing And Discontinued Operation	-	$ -5.93M	$ -5.74M	$ -2.75M	$ -10.29M	$ 1.54M
Normalized Income	-	$ -7.81M	-	$ -2.75M	$ -4.72M	$ 1.54M
Interest Expense	-	-	-	-	-	-
EBIT	-	$ -9.85M	$ -10.78M	$ -2.20M	$ -1.34M	$ 1.77M
EBITDA	-	$ -9.60M	$ -10.46M	$ -1.85M	$ -1.01M	$ 1.95M

Currency in USD

China SXT Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing